Pancreatic Cancer Research

Journal articleClin Lab2019

The Feasibility of Serum Multiple Tumor Markers Test Between Patients with Primary Pancreatic Cancer and Those with Benign Pancreatic Cystic Disease.

Journal
Clin Lab
Published
1 October 2019
Citations
3
Type
Article

These are the paper’s bibliographic details. A summary of its population, design, endpoints and findings, each tied to a quote, has not been written for this paper yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

abstract license unknown

Background Although CA 19-9 is the primary marker used in the diagnosis and treatment of pancreatic cancer, other serum tumor markers have also been utilized in the follow-up of pancreatic cancer. We investigated the clinical utility of CYFRA 21-1, AFP, CEA, CA 19-9, CA 125, NSE, and combinations of these markers in patients with pancreatic cancer. … Excerpt only: this text is the publisher’s. Read it in full at the source.